ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES
A certain success in the treatment of bronchial asthma is associated with the introduction of monoclonal antibodies into the treatment process. They made it possible to improve the control of the disease. A number of original genetically engineered biological drugs, such as benralizumab, reslizumab,...
Main Authors: | V. S. Krysanova, E. D. Ermolaeva, T. N. Ermolaeva, M. V. Davydovskaya, K. A. Kokushkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2021-08-01
|
Series: | Фармация и фармакология (Пятигорск) |
Subjects: | |
Online Access: | https://www.pharmpharm.ru/jour/article/view/864 |
Similar Items
-
Dupilumab in the treatment of severe non-control broncial asthma — economic aspects
by: A. S. Salasyuk, et al.
Published: (2019-10-01) -
Th e clinical-economic analysis of Dupilumab in severe asthma
by: I. S. Krysanov, et al.
Published: (2021-02-01) -
Modeling of the impact of biological drugs in the economic burden of severe asthma
by: S. K. Zyryanov, et al.
Published: (2020-01-01) -
Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
by: I. S. Krysanov, et al.
Published: (2020-09-01) -
Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma
by: A. G. Tolkushin, et al.
Published: (2019-08-01)